Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness

Quan, Mei Yu; Guo, Qiang; Liu, Jiayu; Yang, Ruo; Bai, Jing; Wang, Wei; Cai, Yiqi; Han, Rui; Lv, Yu Qing; Ding, Li; Billadeau, Daniel D.; Lou, Zhenkun; Bellusci, Savério; Li, Xiaokun; Zhang, Jin San

doi:10.3389/fcell.2020.594589

Search citation statements

Order By: Relevance

Paper Sections

Select...

Fibroblast Growth Factor Receptors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the phosphorylated tyrosine residues of GRB2 are captured by the phosphoinositide 3 kinase (PI3K) containing a SH2 domain, thus initiating the activation of PI3K-AKT signaling pathway. The downstream effector molecules of AKT vary, including the well-known mTOR, which is closely related to cell metabolism, transcription and so forth ( Quan et al, 2020 ).…”

Section: Fibroblast Growth Factor Receptorsmentioning

confidence: 99%

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

Zheng

Zhang

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Targeted therapy is a groundbreaking innovation for cancer treatment. Among the receptor tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial attention as promising therapeutic targets due to their fundamental biological functions and frequently observed abnormality in tumors. In the past 2 decades, several generations of FGFR kinase inhibitors have been developed. This review starts by introducing the biological basis of FGF/FGFR signaling. It then gives a detailed description of different types of small-molecule FGFR inhibitors according to modes of action, followed by a systematic overview of small-molecule-based therapies of different modalities. It ends with our perspectives for the development of novel FGFR inhibitors.

show abstract

Section: Fibroblast Growth Factor Receptorsmentioning

confidence: 99%